Enhancing Anti-Tumor Activity of Sorafenib Mesoporous Silica Nanomatrix in Metastatic Breast Tumor and Hepatocellular Carcinoma via the Co-Administration with Flufenamic Acid

INTRODUCTION: Because tumor-associated inflammation is a hallmark of cancer treatment, in the present study, sorafenib mesoporous silica nanomatrix (MSNM@SFN) co-administrated with flufenamic acid (FFA, a non-steroidal anti–inflammatory drug (NSAID)) was investigated to enhance the anti-tumor activi...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zhuo-Yue, Yin, Yi-Fan, Guo, Yang, Li, Hui, Xu, Mei-Qi, Liu, Man, Wang, Jing-Ru, Feng, Zhen-Han, Duan, Xiao-Chuan, Zhang, Shuang, Zhang, Shuai-Qiang, Wang, Guang-Xue, Liao, Ai, Wang, Shu-Min, Zhang, Xuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083629/
https://www.ncbi.nlm.nih.gov/pubmed/32214813
http://dx.doi.org/10.2147/IJN.S240436

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083629/
https://www.ncbi.nlm.nih.gov/pubmed/32214813
http://dx.doi.org/10.2147/IJN.S240436

Ejemplares similares